IL-2 adds only toxicity to neuroblastoma antibody tx

CHICAGO – Adding the cytokine IL-2 to front-line therapy with the anti-GD2 antibody ch14.18/CHO provided no additional survival benefit and only added to toxicity in the treatment of pediatric...
Source: Clinical Neurology News - Category: Neurology Source Type: news